Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP grew its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 27.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 487,863 shares of the company's stock after purchasing an additional 104,371 shares during the period. Rock Springs Capital Management LP owned approximately 0.77% of Vera Therapeutics worth $20,632,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Huntington National Bank purchased a new stake in Vera Therapeutics during the fourth quarter worth about $26,000. AlphaQuest LLC purchased a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $34,000. KBC Group NV boosted its stake in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the period. Finally, Moors & Cabot Inc. purchased a new position in Vera Therapeutics in the 4th quarter valued at approximately $220,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Up 4.4 %

Shares of NASDAQ:VERA traded up $0.95 during midday trading on Wednesday, hitting $22.34. 1,124,338 shares of the company's stock traded hands, compared to its average volume of 749,365. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a market cap of $1.42 billion, a PE ratio of -8.56 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm's fifty day moving average price is $25.46 and its two-hundred day moving average price is $36.13.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VERA has been the topic of several research reports. Wolfe Research assumed coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. Guggenheim raised their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.